+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID06545955

Evaluating Intravesical Nadofaragene Firadenovec Alone or with Chemotherapy for High-grade BCG Unresponsive Non-Muscle Invasive Bladder Cancer

Led by Ferring Pharmaceuticals · Updated on 2026-10-30

250

Participants Needed

81

Research Sites

130 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and efficacy of intravesical nadofaragene firadenovec alone or combined with chemotherapy or immunotherapy in participants with high-grade Bacillus Calmette-Guerin BCG unresponsive non-muscle invasive bladder cancer NMIBC with carcinoma in situ CIS high-grade TaT1. This pivotal phase 3 trial builds on prior findings where 53.4% of subjects achieved a complete response at 3 months, aiming to offer new options for patients unlikely to benefit from further BCG treatment. Participants are randomly assigned to one of two study groups nadofaragene firadenovec alone or nadofaragene firadenovec combined with sequential intravesical gemcitabine and docetaxel chemotherapy. The trial originally included a third arm with pembrolizumab infusion, but this arm is closed to new participants. Treatment involves intravesical bladder instillation of the study drugs, with pembrolizumab delivered by intravenous infusion for patients already enrolled in that arm. During the study, participants undergo regular assessments including evaluations of complete response at 3 and 6 months, durability of response up to 24 months, monitoring for disease progression, cystectomy-free survival, pathological staging, and overall survival up to 36 months. Safety is monitored through adverse event tracking. Participants are expected to be available for the entire study duration, which extends to 2030, allowing long-term observation of treatment effects and disease status.

CONDITIONS

Brief Title

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

Research Team

F

Ferring Pharmaceuticals

F

Ferring Pharmaceuticals

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here